JOHN TIMKO: Open Payments
NPI 1700992948 · WYOMISSING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$47,383 in 180 payments from 13 companies in 2025. Trend: 2023 $28,726 · 2024 $51,737 · 2025 $47,383
Speaker / faculty: $43,957Food & beverage: $3,315Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 48 | $45,567 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 33 | $350 |
| Neurocrine BioSciences, Inc. | 13 | $280 |
| Alkermes, Inc. | 11 | $227 |
| E.R. Squibb & Sons, L.L.C. | 28 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $171 |
| Teva Pharmaceuticals USA, Inc. | 4 | $160 |
| Axsome Therapeutics, Inc. | 11 | $138 |
| Lundbeck LLC | 6 | $134 |
| Vanda Pharmaceuticals Inc. | 4 | $86 |
Products named: REXULTI, CAPLYTA, INGREZZA, LYBALVI, COBENFY, TRINTELLIX, Auvelity, FANAPT.
Industry payments across PA — which companies pay providers there.
